Dr. Bruno Bastos MD, medical oncologist with #MiamiCancerInstitute in a piece, highlighting a new therapy combination utilizing #tpst1120 for patients with #renalcellcarcinoma . Learn more!
targetedonc.com/view/tpst-1120…

TPST1120 not only increases efficacy of the current standard of care but also expends the addressable market of the SOC in PD-1 negative patients which accounts for about 50% of the population! This is huge!

P1 trial of TPST1120 (PPARα antagonist)
pubmed.ncbi.nlm.nih.gov/38551394/
➡️Metabolic target directly impairs tumor growth & reprograms TME
➡️SD with monotherapy & responses in combo w/ PD1 (2PR w/ prior anti-PD1)
➡️P2 ongoing (TSPT1120+bev/ateo) in #HCC

Jjhound Not sure if you cover TPST and have any idea around it’s leading program tpst1120.

Interesting data from Roche/Morpheus #HCC program: bev/atezo+/-TPST1120

TSPT1120 = 'metabolic CPI' targeting PPARa

At early timepoint:
🔼ORR (30% vs. 17.2%)
🔼patients on tx (47.5% vs 23.3%)

bev/atezo/TPST1120 is a promising HCC triplet

finance.yahoo.com/news/tempest-a…

#Tempest to Present #Biomarker Data for  #TPST1120 at the #SITCSpringScientificMeeting23 $TPST 1stoncology.com/blog/tempest-t…

Another thread on the mechanism of the drug #TPST1120 directly targeting #PPARα
#Oncology #Cancer

x.com/eastvillagetwt…

#Tempest to Report Early Results from Global Randomized Phase 1b/2 Combination Study of #TPST1120 in First-Line #HepatocellularCarcinoma $TPST 1stoncology.com/blog/tempest-t…

#Tempest Announces Positive Early Results from Global Randomized Phase 1b/2 Combination Study of #TPST1120 in First-Line #HepatocellularCarcinoma $TPST 1stoncology.com/blog/tempest-a…

#Tempest Presents Data Showing #TPST1120 Induced #Pharmacodynamic Changes Consistent with Clinical Benefit Observed in Patients with #Cancer #SITC22 $TPST 1stoncology.com/blog/tempest-p…

#Tempest Announces Data Presentations, including a Late-Breaking Presentation on #TPST1120 at the #SITC22 Annual Meeting $TPST 1stoncology.com/blog/tempest-a…

#Tempest Announces First Patient Dosed in Randomized Study Evaluating #TPST1120 in First-Line Regimen for #HepatocellularCarcinoma in Clinical Collaboration with #Roche $TPST 1stoncology.com/blog/tempest-a…